ENTG - This Semiconductor Company Is Looking to Double Down On Pharmaceuticals
When the healthcare industry is looking for a safe, effective way to produce and distribute vaccines to battle a global pandemic, turning to a processor from the semiconductor industry may not be the first thought for a solution.
But when asked a similar question about how gaps in advanced process control environments (like vaccine production) in healthcare can be helped by a company that focuses primarily in the semiconductor industry, Life Sciences Chief of Entegris (NASDAQ: ENTG) John Lynch stated, "We've been serving customers in semiconductor and other highly complex manufacturing environments for over 50 years, and that makes us well suited to address some of the similar needs around yield and purity with the pharmaceutical industry."
It's that type of thought process from Lynch that led Entegris to invest in itself, putting $10 million toward processing assemblies in 2020 and designating an additional $30 million for this year.
For further details see:
This Semiconductor Company Is Looking to Double Down On Pharmaceuticals